In this episode of The Common Sense MD, Dr. Tom Rogers dives into the revolutionary practice of microdosing GLP-1 medications, a class of drugs originally developed for diabetes but now widely recognized for their impressive benefits in weight loss, metabolic health, and beyond. Dr. Rogers shares his own experience with microdosing tirzepatide—even though he isn’t diabetic or obese—and discusses why these medications are game-changers not just for diabetes and obesity, but for a wide array of health issues.
He breaks down how GLP-1 and GIP incretin hormones work, the evolution of these medications, and what makes microdosing effective and accessible for more people. Dr. Rogers also covers the many potential off-label benefits: from cardiovascular and neuroprotective effects, to improved liver function, help with conditions like PCOS and migraines, addiction support, and more. He addresses the cost and accessibility of these drugs, especially through compounding pharmacies, and emphasizes safety, monitoring, and individualized care.
Whether you’re a patient interested in the latest in metabolic medicine or just curious about GLP-1s, this episode offers a clear, practical, and insightful look at how these medications can fit into a broader strategy for health, longevity, and well-being.
What did you think of this episode of the podcast? Let us know by leaving a review!
Connect with Performance Medicine!
Check out our new online vitamin store:https://performancemedicine.net/shop/
Sign up for our weekly newsletter: https://performancemedicine.net/doctors-note-sign-up/
YouTube: Performance Medicine